Bank of Montreal Can grew its stake in Aratana Therapeutics Inc (NASDAQ:PETX) by 152.9% during the 3rd quarter, HoldingsChannel reports. The fund owned 51,360 shares of the biopharmaceutical company’s stock after purchasing an additional 31,053 shares during the quarter. Bank of Montreal Can’s holdings in Aratana Therapeutics were worth $301,000 as of its most recent SEC filing.

A number of other institutional investors also recently added to or reduced their stakes in PETX. Engaged Capital LLC boosted its holdings in Aratana Therapeutics by 20.0% in the second quarter. Engaged Capital LLC now owns 2,400,000 shares of the biopharmaceutical company’s stock worth $10,200,000 after acquiring an additional 400,000 shares in the last quarter. Massachusetts Financial Services Co. MA raised its stake in shares of Aratana Therapeutics by 36.2% in the second quarter. Massachusetts Financial Services Co. MA now owns 1,376,198 shares of the biopharmaceutical company’s stock worth $5,849,000 after purchasing an additional 365,750 shares during the last quarter. BlackRock Inc. raised its stake in shares of Aratana Therapeutics by 11.5% in the second quarter. BlackRock Inc. now owns 3,348,240 shares of the biopharmaceutical company’s stock worth $14,231,000 after purchasing an additional 345,204 shares during the last quarter. Dimensional Fund Advisors LP raised its stake in shares of Aratana Therapeutics by 30.5% in the first quarter. Dimensional Fund Advisors LP now owns 785,096 shares of the biopharmaceutical company’s stock worth $3,462,000 after purchasing an additional 183,294 shares during the last quarter. Finally, Grandeur Peak Global Advisors LLC raised its stake in shares of Aratana Therapeutics by 29.4% in the second quarter. Grandeur Peak Global Advisors LLC now owns 712,138 shares of the biopharmaceutical company’s stock worth $3,027,000 after purchasing an additional 161,675 shares during the last quarter. 64.78% of the stock is currently owned by institutional investors and hedge funds.

Several research firms have recently weighed in on PETX. Zacks Investment Research cut Aratana Therapeutics from a “buy” rating to a “hold” rating in a research note on Thursday, November 8th. BidaskClub upgraded Aratana Therapeutics from a “buy” rating to a “strong-buy” rating in a research note on Thursday, November 8th. HC Wainwright set a $10.00 price target on Aratana Therapeutics and gave the stock a “buy” rating in a research note on Monday, November 5th. Finally, ValuEngine upgraded Aratana Therapeutics from a “sell” rating to a “hold” rating in a research note on Monday, October 22nd. Two equities research analysts have rated the stock with a hold rating, four have given a buy rating and one has assigned a strong buy rating to the stock. Aratana Therapeutics has an average rating of “Buy” and a consensus target price of $8.15.

PETX stock opened at $6.49 on Tuesday. The firm has a market capitalization of $318.98 million, a PE ratio of -6.69 and a beta of 1.95. The company has a debt-to-equity ratio of 0.02, a current ratio of 3.17 and a quick ratio of 2.70. Aratana Therapeutics Inc has a 1-year low of $3.67 and a 1-year high of $7.28.

Aratana Therapeutics (NASDAQ:PETX) last posted its quarterly earnings data on Thursday, November 1st. The biopharmaceutical company reported ($0.13) EPS for the quarter, beating analysts’ consensus estimates of ($0.16) by $0.03. The company had revenue of $21.56 million during the quarter, compared to analysts’ expectations of $5.70 million. Aratana Therapeutics had a negative return on equity of 15.08% and a negative net margin of 52.94%. As a group, research analysts anticipate that Aratana Therapeutics Inc will post -0.25 EPS for the current fiscal year.

In related news, insider Ernst Heinen sold 19,308 shares of the company’s stock in a transaction on Wednesday, November 7th. The stock was sold at an average price of $6.95, for a total transaction of $134,190.60. Following the completion of the sale, the insider now owns 135,694 shares in the company, valued at $943,073.30. The transaction was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Also, CEO Peter Steven St sold 75,000 shares of the company’s stock in a transaction on Friday, September 21st. The shares were sold at an average price of $6.06, for a total value of $454,500.00. Following the sale, the chief executive officer now owns 574,233 shares of the company’s stock, valued at approximately $3,479,851.98. The disclosure for this sale can be found here. In the last quarter, insiders have sold 106,513 shares of company stock valued at $660,966. 5.30% of the stock is owned by company insiders.

ILLEGAL ACTIVITY WARNING: “Bank of Montreal Can Has $301,000 Holdings in Aratana Therapeutics Inc (PETX)” was first posted by Daily Political and is the sole property of of Daily Political. If you are viewing this piece on another website, it was illegally copied and reposted in violation of US and international copyright & trademark legislation. The correct version of this piece can be accessed at https://www.dailypolitical.com/2018/11/20/bank-of-montreal-can-has-301000-holdings-in-aratana-therapeutics-inc-petx.html.

About Aratana Therapeutics

Aratana Therapeutics, Inc, a pet therapeutics company, focuses on the licensing, development, and commercialization of therapeutics for dogs and cats in the United States and Belgium. Its product portfolio includes multiple therapeutics and therapeutic candidates in development consisting of small molecule pharmaceuticals and biologics.

See Also: Intrinsic Value

Want to see what other hedge funds are holding PETX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Aratana Therapeutics Inc (NASDAQ:PETX).

Institutional Ownership by Quarter for Aratana Therapeutics (NASDAQ:PETX)

Receive News & Ratings for Aratana Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aratana Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.